
This review assesses subcutaneous immunotherapy (SCIT) adherence in real-world settings, as adherence is often studied in closely monitored trials. The researchers conducted a literature search and found 17 articles that met the inclusion criteria, with a total of 263,221 patients. The study found that SCIT persistence and adherence rates are generally poor, with rates ranging widely and explained in part by inter-study differences in measuring and reporting adherence-related findings. Inconvenience was cited as the most common reason for discontinuing SCIT. The researchers suggest that future studies on SCIT adherence should follow concordant definitions of persistence and adherence in addition to standardized reporting metrics.
Like
Save
Share